BIRCH team
Beth Bell COVID-19 vaccine
June 22, 2022 | Health News

Why America Doesn't Trust the CDC

Newsweek

People don't trust the CDC. Here's one example illustrating why. Two weeks ago, with no outcomes data on COVID-19 booster shots for 5-to-11-year-olds, the Centers for Disease Control (CDC) vigorously recommended the booster for all 24 million American children in that age group. The CDC cited a small Pfizer study of 140 children that showed boosters elevated their antibody levels—an outcome known to be transitory.

Dr. Beth Bell, Clinical Professor of Global Health at UW, is quoted. 

two people standing on either side of a body of water with vaccines piled behind one side
COVID-19 vaccine
March 10, 2022 | Department News

A Global Day of Action to End Vaccine Apartheid

March 11 marks the two-year anniversary of the World Health Organization declaring COVID-19 a global pandemic. The Department of Global Health will be participating in the Global Day of Action to advocate for the removal of pharmaceutical monopolies on COVID tests, vaccines, and treatments to allow low- and middle-income countries to produce the life-saving medicines their populations desperately need. 

Graphic with the words: Summary of Evidence Related to COVID-19 Vaccine Effectiveness and Breakthrough Infections
COVID-19 Literature Situation Report COVID-19 vaccine
May 25, 2021 | Department News

Summary of Evidence Related to COVID-19 Vaccine Effectiveness and Breakthrough Infections

There are currently three COVID-19 vaccines authorized under an Emergency Use Authorization in the US and across the US, everyone 16 years or older is currently eligible for vaccination with at least one of the vaccines, with expansion of eligibility down to age 12 likely soon. The vaccine coverage among eligible individuals remains uneven, but high coverage among adults has been achieved in some settings.

BIRCH team
COVID-19 COVID-19 vaccine Ruanne Barnabas
March 22, 2021 | Health News

Double Dose of Debate: Opinions Vary on Timing of COVID Vaccine Shots as Potential 4th Wave Looms (includes Ruanne Barnabas)

by Lisa Stiffler  / March 19, 2021

With COVID-19 vaccines still in limited supply and case counts threatening to resurge, there is a debate over the benefits of giving more people their first shot and waiting a longer time to administer the second dose, or whether to stay the course and prioritize getting both doses of the Pfizer and Moderna vaccine into arms as quickly as possible.

BIRCH team
COVID-19 vaccine COVID-19 variants Wes Van Voorhis UW Alliance for Pandemic Preparedness
January 29, 2021 | Health News

United World Antiviral Research Network (UWARN) Partners Collaborate to Expand Understanding of New COVID Variants, Key to Future Vaccine Development

The recent recognition of new COVID-19 variants, first detected in South Africa (B.1.135, 501Y.V2), Brazil (P1) and the UK (B.1.1.7) – and the variants’ potential to disrupt vaccine effectiveness and protection from prior COVID-19 infection – is an urgent concern that UWARN partners around the globe are collaborating on to understand.

Ruanne Barnabas COVID-19 vaccine
January 04, 2021 | Department News

Opinion: Specialists Back Single-Dose Vaccine Strategy for COVID-19 (includes Ruanne Barnabas)

Even partial protection of one dose could be enough to slow the spread of the virus, the UW Medicine researchers argue in a paper.

MEDIA CONTACT: Susan Gregg - 206.616.6730, sghanson@uw.edu

Giving one dose of the COVID-19 vaccines currently approved in the United States could curtail the spread of the SARS-CoV-19 in the community more quickly than the recommended two doses, say two vaccine experts at the University of Washington School of Medicine.

COVID-19 vaccine Scott McClelland
December 30, 2020 | Department News

UW Medicine starts Novavax COVID-19 vaccine clinical trial (includes Scott McClelland)

Volunteer enrollment begins for Phase III clinical trial that will determine the efficacy of Novavax vaccine candidate.

UW Medicine investigators are starting volunteer enrollment for an investigational COVID-19 vaccine clinical trial. The Phase III study will examine whether the Novavax vaccine candidate can protect against SARS-CoV-2, the coronavirus responsible for COVID-19.

Pages